(7) Accrued Liabilities for Abraxis_BioScience (ABII)

close
close
close
close

Send us Feedback

Abraxis BioScience (ABII)

	SUMMARY

	BULLS

	BEARS

	TOPICS

	DATA CENTRAL

	STOCK CHART

	SEC FILINGS

	BALANCE

	INCOME

	CASH FLOW

ABII » Topics » (7) Accrued Liabilities

This excerpt taken from the ABII 10-K filed Mar 12, 2010.

8. Accrued Liabilities

Accrued liabilities consisted of the following at:


		December 31,
		2009			2008
		(in thousands)
Sales and marketing		$	5,226		$	2,631
Marketing rebates			9,513			5,552
Payroll and employee benefits			23,660			14,797
Legal			30,491			17,632
Liability award plan			7,986			—
Milestone			—			3,950
Other			11,847			8,458

		$	88,723		$	53,020

79

Table of Contents

This excerpt taken from the ABII 10-Q filed May 8, 2009.

(6) Accrued Liabilities

Accrued liabilities consisted of the following at:


		March 31, 2009			December 31, 2008
		(in thousands)
Sales and marketing		$	14,693		$	13,125
Payroll and employee benefits			11,366			14,797
Legal and insurance			21,324			17,632
Milestone			—			3,950
Other			1,959			3,516

		$	49,342		$	53,020

These excerpts taken from the ABII 10-K filed Mar 6, 2009.

6. Accrued Liabilities

Accrued liabilities consisted of the following at:


		December 31,
		2008			2007
		(in thousands)
Sales and marketing		$	13,125		$	15,466
Payroll and employee benefits			14,797			12,249
Legal and insurance			17,632			12,234
RSU Plan II			—			12,614
Milestone			3,950			—
Other			3,516			2,364

		$	53,020		$	54,927

6. Accrued Liabilities

Accrued liabilities consisted of the following at:


		December 31,
		2008			2007
		(in thousands)
Sales and marketing		$	13,125		$	15,466
Payroll and employee benefits			14,797			12,249
Legal and insurance			17,632			12,234
RSU Plan II			—			12,614
Milestone			3,950			—
Other			3,516			2,364

		$	53,020		$	54,927

This excerpt taken from the ABII 10-Q filed Nov 14, 2008.

(7) Accrued Liabilities

Accrued liabilities consisted of the following at:


		September 30, 2008			December 31, 2007
		(in thousands)
Sales and marketing		$	12,720		$	15,466
Payroll and employee benefits			14,796			12,249
Legal and insurance			12,907			12,234
Restricted stock units – short-term			—			12,614
Milestone payments - current			4,590			—
Other			3,735			2,364

		$	48,748		$	54,927

This excerpt taken from the ABII 10-Q filed Aug 14, 2008.

(6) Accrued Liabilities

Accrued liabilities consisted of the following at:


		June 30, 2008			December 31, 2007
		(in thousands)
Sales and marketing		$	12,728		$	15,466
Payroll and employee benefits			11,758			12,249
Legal and insurance			11,906			12,234
Restricted stock units – short-term			—			12,614
Other			7,721			2,364

		$	44,113		$	54,927

This excerpt taken from the ABII 10-Q filed May 15, 2008.

(5) Accrued Liabilities

Accrued liabilities consisted of the following at:


		March 31, 2008			December 31, 2007
		(in thousands)
Sales and marketing		$	14,424		$	15,466
Payroll and employee benefits			15,400			12,249
Legal and insurance			12,767			12,234
Restricted stock units – short-term			13,094			12,614
Other			2,393			2,364

		$	58,078		$	54,927

10

Table of Contents

This excerpt taken from the ABII 10-K filed Mar 31, 2008.

5. Accrued Liabilities

Accrued liabilities consisted of the following at:


		December 31,
		2007			2006
		(in thousands)
Sales and marketing		$	15,466		$	9,983
Payroll and employee benefits			12,249			6,733
Legal and insurance			12,234			1,035
RSU Plan II—Short term			12,614			9,670
Other			2,364			2,486

		$	54,927		$	29,907

Additionally, legal-related expense of $23.8 million is accounted for in selling, general and administrative expense for the year ended December 31, 2007.

This excerpt taken from the ABII 8-K filed Nov 8, 2007.

(7) Accrued Liabilities

Accrued liabilities consisted of the following at:


		June 30, 2007			December 31, 2006
		(in thousands)
Sales and marketing		$	17,250		$	9,983
Payroll and employee benefits			7,730			6,733
Legal and insurance			26,426			1,035
RSU—short term			6,948			9,670
Other			2,272			1,469

		$	60,626		$	28,890

F-37

Table of Contents

EXCERPTS ON THIS PAGE:

10-K	Mar 12, 2010

10-Q	May 8, 2009

10-K (2 sections)	Mar 6, 2009

10-Q	Nov 14, 2008

10-Q	Aug 14, 2008

10-Q	May 15, 2008

10-K	Mar 31, 2008

8-K	Nov 8, 2007

RELATED TOPICS for ABII:

"(7) Accrued Liabilities" elsewhere:

Cypress Bioscience (CYPB)
Diversa (DVSA)
Ev3 (EVVV)
Fibrocell Science, Inc. (ILE)

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.

About | Blog | Press | Feedback | Help | Get involved

Mobile | Advertise | Licensing & Partnerships | Blogger Tools | Jobs